Does TRT raise blood pressure? On average, yes, and modestly. After reviewing required 24-hour monitoring studies, FDA concluded in 2025 that testosterone raises blood pressure across all products, class-wide (FDA, 2025). Label studies show average systolic increases of roughly 1.7 to 4.9 mm Hg, with wide variation between individual men. That calls for screening and follow-up. It is not a reason for panic, and it is not the same as a hypertension diagnosis.
Key takeaways
- FDA said completed ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products, and in 2025 it required blood pressure information on testosterone labels across the class (FDA, 2025).
- Average systolic increases in label studies ranged from about 1.7 to 4.9 mm Hg depending on product and study, with wide variation between individual men.
- Oral testosterone undecanoate labels have carried a boxed blood pressure warning, and Kyzatrex's label records that boxed warning as removed in July 2025, with blood pressure moved to Warnings and Precautions (Kyzatrex label, 2025).
- A rise in average blood pressure is not the same as developing hypertension, and it is a separate question from heart attack and stroke outcomes.
- That is why responsible testosterone care starts with a live clinician visit, a blood pressure review and lab work, and keeps blood pressure on the follow-up list.
Does TRT raise blood pressure? The short answer
Yes, on average. FDA states that completed ambulatory monitoring studies "confirmed an increase in blood pressure with use of all testosterone products, class-wide" (FDA, 2025).
Blood pressure is reported in millimeters of mercury (mm Hg). Systolic, the top number, is the pressure when the heart beats. Diastolic, the bottom number, is the pressure between beats.
The finding came from a deliberate process. In 2016 and 2017, FDA recommended premarket blood pressure studies for two testosterone products given by two routes, subcutaneous injection (under the skin) and oral. Consistent results raised concern, and in March 2018 FDA required individual ambulatory studies of all testosterone products. On February 28, 2025, it told manufacturers to add product-specific blood pressure data where studies were complete, and a new blood pressure warning where they were not (FDA, 2025).
The average changes are small. Still, the gel 1.62% and Kyzatrex labels both state that blood pressure increases can raise cardiovascular risk over time (testosterone gel 1.62% label; Kyzatrex label, 2025). Read that as a monitoring issue: something to measure and manage, not something to fear or ignore.
Why 24-hour monitoring shows more than an office cuff
Ambulatory blood pressure monitoring (ABPM) can pick up changes that a single office reading misses. In one trial, the same oral testosterone produced different averages depending on how blood pressure was measured.
ABPM uses a portable cuff worn for 24 hours. It takes readings at intervals through the day and during sleep, instead of capturing one moment in a clinic.
Jatenzo's original 2019 label reported that, over 4 months, the drug raised average systolic blood pressure by 4.9 mm Hg by ambulatory monitoring and by 2.8 mm Hg by cuff measurement (Jatenzo label, 2019). Same trial, same drug, a much larger measured effect. FDA built its class-wide requirement around ABPM, and this gap shows why the method matters.
One normal reading at a visit does not settle the question. Trends over time matter more.
What happened to the boxed blood pressure warning in 2025
For Kyzatrex, an oral testosterone undecanoate, the boxed blood pressure warning was removed in July 2025. The blood pressure warning itself is still on its label.
A boxed warning is the most prominent warning FDA requires, printed at the top of a label. Jatenzo's 2019 label opened with "WARNING: BLOOD PRESSURE INCREASES." It said these increases could raise the risk of major adverse cardiovascular events (MACE), meaning outcomes such as heart attack, stroke and cardiovascular death, with greater risk in men with cardiovascular disease or cardiovascular risk factors (Jatenzo label, 2019).
Kyzatrex's current label lists "Boxed Warnings, Blood Pressure Increases Removed 07/2025." Blood pressure now sits in Warnings and Precautions, which still calls for periodic monitoring, especially in men with hypertension (Kyzatrex label, 2025). The verified record here covers Kyzatrex only. Label status can differ by product, so the current label for any specific product is the reference.
A separate change happened in parallel. Based on the TRAVERSE trial, FDA required removal of boxed language about increased adverse cardiovascular outcomes for all testosterone products. It kept the "Limitation of Use" language for age-related hypogonadism, meaning low testosterone attributed only to aging (FDA, 2025). The full sequence is laid out in our testosterone label changes timeline.
Pages that describe a boxed blood pressure warning on Kyzatrex are out of date. Pages that say the blood pressure concern went away with the box are wrong.
Is a rise in blood pressure the same as hypertension?
No. An average shift across a study group is not the same as an individual man developing hypertension, which is persistently elevated blood pressure diagnosed and managed by a clinician.
The gel 1.62% ABPM study shows the difference. Average systolic/diastolic blood pressure rose 1.9/1.3 mm Hg after 16 weeks. Four patients (2.8%), all already taking blood pressure medication, started a new medication or had their regimen adjusted (testosterone gel 1.62% label).
The spread around the average matters too. In the registered trial behind that study, the per-protocol change in 24-hour average systolic pressure was 1.9 ± 8.99 mm Hg in 169 participants (ClinicalTrials.gov, NCT04274894). The ± figure is a standard deviation. A spread that wide means some men rose considerably more than 1.9 mm Hg and some fell. A small average can hide a meaningful change for one person.
TRAVERSE adds the long view. It was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial of testosterone gel in hypogonadal men with, or at high risk for, cardiovascular disease (NEJM, 2023). At 36 months, mean systolic pressure rose 1.0 mm Hg on gel and fell 0.5 mm Hg on placebo, a 1.5 mm Hg difference between groups (testosterone gel 1.62% label). FDA states TRAVERSE found no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism (FDA, 2025).
Both findings are true at once. A small blood pressure difference and heart-event risk answer different questions. For the outcome data, see what TRAVERSE actually showed about heart risk.
Does the form of testosterone change the blood pressure picture?
The label numbers differ by product, but they cannot rank one form as safer than another. The trials differ, none compared forms head to head, and FDA describes the effect as class-wide.
| Product and form | Average change by ABPM | Timepoint |
|---|---|---|
| Jatenzo, oral testosterone undecanoate (2019 label) | +4.9 mm Hg systolic (cuff: +2.8) | 4 months |
| Kyzatrex, oral testosterone undecanoate | +1.7/0.6 mm Hg; +1.8/0.6 mm Hg | 4 months; 6 months |
| Testosterone gel 1.62%, topical | +1.9/1.3 mm Hg | 16 weeks |
| Subcutaneous injectable product | Premarket ABPM results consistent with oral findings; figures not in sources reviewed here | Not stated |
Sources: Jatenzo label, 2019; Kyzatrex label, 2025; testosterone gel 1.62% label; FDA, 2025.
These studies used different populations, durations and analysis sets. Treat them as separate snapshots, not a league table. One pattern stands out: men already on blood pressure medication showed a larger average rise on gel 1.62%, 3.0/2.2 mm Hg (testosterone gel 1.62% label).
These numbers come from the specific products named in each label study. They are not data on New Blue's injectable, cream or oral testosterone protocol, and they do not predict what any one man will see. Which form, if any, is appropriate is a clinician's decision based on your history, readings and labs.
TRT with high blood pressure: evaluation and monitoring
Men with high blood pressure can be evaluated, but uncontrolled hypertension is a firm caution. The testosterone gel 1.62% label says it is not recommended in uncontrolled hypertension (testosterone gel 1.62% label), and Kyzatrex's label calls for periodic monitoring, especially in men with hypertension (Kyzatrex label, 2025).
Treated hypertension is not an automatic no. Men on blood pressure medication were analyzed as a subgroup in the gel study, and the registered trial accounted for hypertension history in its analysis (ClinicalTrials.gov, NCT04274894).
Other medicines count. Drugs that raise blood pressure can add to the effect of testosterone (Kyzatrex label, 2025). Some common over-the-counter decongestants and pain relievers can raise blood pressure too, so bring a full medication and supplement list to your visit.
A responsible evaluation and follow-up typically looks like this:
- Confirm the diagnosis. The Endocrine Society recommends diagnosing hypogonadism only with symptoms plus unequivocally and consistently low testosterone, then looking for the cause. It also suggests against routinely prescribing testosterone to all men 65 or older with low levels (Endocrine Society, 2018).
- Review blood pressure history, current readings and all medications before deciding anything.
- Measure blood pressure periodically during treatment. If it rises, a clinician may start or adjust blood pressure treatment. Kyzatrex's Medication Guide says the drug may need to be stopped if blood pressure cannot be controlled (Kyzatrex label, 2025).
- Follow the lab plan. The guideline covers symptoms, side effects, adherence, serum testosterone and hematocrit, plus prostate cancer risk in the first year (Endocrine Society, 2018). It predates FDA's 2025 blood pressure labeling.
Hematocrit, the share of blood volume made up of red blood cells, is often named online as the cause of blood pressure rises on testosterone. The sources reviewed here do not establish that. FDA's findings rest on their own ambulatory studies, and the guideline lists hematocrit as a separate monitoring item. A normal result on one does not clear the other, so both get checked. Our TRT blood work guide covers the lab side.
A log of home readings helps a clinician see trends. Do not change or stop any prescription on your own; follow your clinician's guidance and pharmacy instructions. Chest pain, severe shortness of breath or new neurological symptoms such as weakness, confusion or trouble speaking need emergency care right away.
Not everyone qualifies. Eligibility depends on your intake, your readings and clinical review, and that's how it should work.
How access works through New Blue
New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.
Every testosterone pathway, whether injectable, cream or oral, is synchronous. That means a live visit with an independent licensed clinician plus lab work. No hormone pathway is form-only.
- Complete an intake covering your symptoms, history, blood pressure and medications.
- Complete lab work and a live visit with an independent licensed clinician.
- The clinician decides whether testosterone is appropriate and, if so, which form.
- If prescribed, a licensed partner pharmacy ships the medication directly to you.
Consultation timing varies by clinician availability. Care is for adults 21 and older and is not for emergencies. Availability varies by state; see state availability. For current pricing, see the injectable testosterone protocol page. New Blue is LegitScript certified. If your request isn't accepted, the hold on your card is released and nothing is charged. If you're not prescribed after your visit, what you paid comes back except the part that covers your lab work and clinician visit; see the refund policy.
Frequently Asked Questions
How much does testosterone raise blood pressure?
In FDA label studies using 24-hour ambulatory monitoring, average systolic increases ranged from about 1.7 to 4.9 mm Hg, depending on the product and the study. Individual results varied widely. In one gel study, the systolic change was 1.9 ± 8.99 mm Hg, so some men rose far more than the average and some fell.
Does testosterone injection raise blood pressure?
FDA concluded that testosterone raises blood pressure across all products, class-wide, which includes injections. In 2016 and 2017, FDA recommended a premarket ambulatory study for a subcutaneous injection product, and the results were consistent with the oral findings. Blood pressure monitoring applies whatever the form.
Is the oral testosterone boxed warning still on the label?
Not on Kyzatrex. Its current label lists the boxed blood pressure warning as removed in July 2025, with blood pressure moved to Warnings and Precautions and periodic monitoring still advised. Label status can differ by product, so check the current label for the specific product in question.
Should I stop TRT if my blood pressure goes up?
Contact your prescribing clinician rather than stopping or changing anything on your own. Adjusting blood pressure treatment or stopping testosterone are clinician decisions based on your readings, and Kyzatrex's label says it may need to be stopped if blood pressure cannot be controlled. Seek emergency care for chest pain, severe shortness of breath or new neurological symptoms.
Can I start TRT if I already take blood pressure medication?
Possibly. Men with treated hypertension were included in FDA-required ambulatory studies, though they showed a larger average rise on gel. The testosterone gel 1.62% label says it is not recommended in uncontrolled hypertension, so a licensed clinician weighs your readings, medications and labs before deciding.
Can TRT lower blood pressure?
The sources reviewed here do not support testosterone as a way to lower blood pressure. FDA's conclusion points the other way, toward a modest average increase. High blood pressure needs its own evaluation and management.
Sources
- FDA issues class-wide labeling changes for testosterone products. U.S. Food and Drug Administration, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
- JATENZO (testosterone undecanoate) original prescribing information, NDA 206089. U.S. Food and Drug Administration (Drugs@FDA), 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206089s000lbl.pdf
- KYZATREX (testosterone undecanoate) capsules: Prescribing Information (Revised 07/2025). U.S. Food and Drug Administration (Drugs@FDA) / DailyMed, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213953s005lbl.pdf
- TESTOSTERONE gel 1.62%: Drug Label Information. DailyMed, U.S. National Library of Medicine, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44a04f66-fd2a-45c7-934e-8f14c023ce14
- A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism (NCT04274894). ClinicalTrials.gov, 2024. https://clinicaltrials.gov/study/NCT04274894
- Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine, 2023. https://doi.org/10.1056/NEJMoa2215025
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
Medical disclaimer: This article is for educational purposes only and is not medical advice. Decisions about testosterone therapy, blood pressure management and any other treatment are made by an independent licensed clinician based on your individual history, evaluation and lab results. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.